About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker SNY · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Nov 10, 2026RIFADIN
RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050627 ↗
Jul 24, 2026AVAPRO
IRBESARTAN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA020757 ↗
Jul 9, 2026SARCLISA ESCENA
ISATUXIMAB-IRFC
SNY
Sanofi-Aventis U.S. LLC
Biologic (BLA)
Type 3 - New Dosage Form
BLA761445 ↗
Jun 26, 2026SARCLISA
ISATUXIMAB-IRFC
SNY
Sanofi Aventis US
Biologic (BLA), supplement
Labeling
BLA761113 ↗
Mar 12, 2026SOLIQUA 100/33
INSULIN GLARGINE; LIXISENATIDE
SNY
Sanofi-Aventis US
Biologic (BLA), supplement
Labeling
BLA208673 ↗
Mar 12, 2026ADLYXIN
LIXISENATIDE
SNY
Sanofi-Aventis US
Biologic (BLA), supplement
Labeling
BLA208471 ↗
Feb 11, 2026AUBAGIO
TERIFLUNOMIDE
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA202992 ↗
Feb 2, 2026PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA008316 ↗
Jan 27, 2026CAPRELSA
VANDETANIB
SNY
Genzyme Corp
New drug (NDA), supplement
Labeling
NDA022405 ↗
Jan 27, 2026PRIFTIN
RIFAPENTINE
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA021024 ↗
Jan 12, 2026CEREZYME
IMIGLUCERASE
SNY
Genzyme
Biologic (BLA), supplement
Efficacy
BLA020367 ↗
Dec 5, 2025RIFATER
ISONIAZID; PYRAZINAMIDE; RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050705 ↗
Dec 5, 2025RIFADIN
RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050627 ↗
Dec 5, 2025RIFADIN
RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050420 ↗
Oct 8, 2025RIFATER
ISONIAZID; PYRAZINAMIDE; RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050705 ↗
Oct 8, 2025RIFADIN
RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050627 ↗
Oct 8, 2025RIFADIN
RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050420 ↗
Sep 23, 2025CAPRELSA
VANDETANIB
SNY
Genzyme Corp
New drug (NDA), supplement
REMS
NDA022405 ↗
Aug 29, 2025WAYRILZ
RILZABRUTINIB
SNY
Genzyme Corp
New drug (NDA)
Type 1 - New Molecular Entity
NDA219685 ↗
Aug 1, 2025AVALIDE
HYDROCHLOROTHIAZIDE; IRBESARTAN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA020758 ↗
Aug 1, 2025AVAPRO
IRBESARTAN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA020757 ↗
Jun 26, 2025CAPRELSA
VANDETANIB
SNY
Genzyme Corp
New drug (NDA), supplement
REMS
NDA022405 ↗
Jun 11, 2025HECTOROL
DOXERCALCIFEROL
SNY
Sanofi
New drug (NDA), supplement
Efficacy
NDA020862 ↗
May 28, 2025SOLIQUA 100/33
INSULIN GLARGINE; LIXISENATIDE
SNY
Sanofi-Aventis US
Biologic (BLA), supplement
Labeling
BLA208673 ↗
May 28, 2025ADLYXIN
LIXISENATIDE
SNY
Sanofi-Aventis US
Biologic (BLA), supplement
Labeling
BLA208471 ↗
May 14, 2025CAPRELSA
VANDETANIB
SNY
Genzyme Corp
New drug (NDA), supplement
Labeling
NDA022405 ↗
Mar 28, 2025QFITLIA
FITUSIRAN SODIUM
SNY
Genzyme Corp
New drug (NDA)
Type 1 - New Molecular Entity
NDA219019 ↗
Letter or label ↗
Mar 10, 2025PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA008316 ↗
Feb 14, 2025MERILOG
INSULIN ASPART-SZJJ
SNY
Sanofi-Aventis U.S. LLC
Biologic (BLA)
UNKNOWN
BLA761325 ↗
Feb 5, 2025RIFATER
ISONIAZID; PYRAZINAMIDE; RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050705 ↗
Jan 2, 2025Synvisc, Synvisc-One
Acid, hyaluronic, intraarticular
SNY
Sanofi Genzyme Corp.
Device approval (PMA), supplement
Special (Immediate Track)
P940015 ↗
Dec 30, 2024LUMIZYME
ALGLUCOSIDASE ALFA
SNY
Genzyme
Biologic (BLA), supplement
Labeling
BLA125291 ↗
Dec 20, 2024XENPOZYME
OLIPUDASE ALFA-RPCP
SNY
Genzyme Corp
Biologic (BLA), supplement
Labeling
BLA761261 ↗
Dec 19, 2024CEREZYME
IMIGLUCERASE
SNY
Genzyme
Biologic (BLA), supplement
Labeling
BLA020367 ↗
Nov 1, 2024SOLIQUA 100/33
INSULIN GLARGINE; LIXISENATIDE
SNY
Sanofi-Aventis US
Biologic (BLA), supplement
Labeling
BLA208673 ↗
Nov 1, 2024ADLYXIN
LIXISENATIDE
SNY
Sanofi-Aventis US
Biologic (BLA), supplement
Labeling
BLA208471 ↗
Oct 25, 2024SARCLISA
ISATUXIMAB-IRFC
SNY
Sanofi Aventis US
Biologic (BLA), supplement
Efficacy
BLA761113 ↗
Oct 25, 2024SARCLISA
ISATUXIMAB-IRFC
SNY
Sanofi Aventis US
Biologic (BLA), supplement
Efficacy
BLA761113 ↗
Oct 10, 2024RIFATER
ISONIAZID; PYRAZINAMIDE; RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050705 ↗
Oct 10, 2024RIFADIN
RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050627 ↗
Letter or label ↗
Oct 10, 2024RIFADIN
RIFAMPIN
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA050420 ↗
Letter or label ↗
Sep 20, 2024FEXINIDAZOLE
FEXINIDAZOLE
SNY
Sanofi
New drug (NDA), supplement
Labeling
NDA214429 ↗
Letter or label ↗
Sep 20, 2024FEXINIDAZOLE
FEXINIDAZOLE
SNY
Sanofi
New drug (NDA), supplement
Labeling
NDA214429 ↗
Letter or label ↗
Sep 20, 2024SARCLISA
ISATUXIMAB-IRFC
SNY
Sanofi Aventis US
Biologic (BLA), supplement
Efficacy
BLA761113 ↗
Aug 29, 2024TOUJEO, TOUJEO MAX, INSULIN GLARGINE U-300 MAX, INSULIN GLA…
INSULIN GLARGINE RECOMBINANT
SNY
Sanofi US Services
Biologic (BLA), supplement
Labeling
BLA206538 ↗
Jul 10, 2024FABRAZYME
AGALSIDASE BETA
SNY
Genzyme
Biologic (BLA), supplement
Labeling
BLA103979 ↗
Jul 10, 2024CEREZYME
IMIGLUCERASE
SNY
Genzyme
Biologic (BLA), supplement
Labeling
BLA020367 ↗
Jun 28, 2024ARAVA
LEFLUNOMIDE
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA020905 ↗
Jun 10, 2024AUBAGIO
TERIFLUNOMIDE
SNY
Sanofi Aventis US
New drug (NDA), supplement
Labeling
NDA202992 ↗
Jun 10, 2024KEVZARA
SARILUMAB
SNY
Sanofi Synthelabo
Biologic (BLA), supplement
Efficacy
BLA761037 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:40 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates